Analysts Set The Chemours Company (NYSE:CC) PT at $17.56

Shares of The Chemours Company (NYSE:CC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine ratings firms that are presently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $17.22.

CC has been the subject of a number of recent analyst reports. The Goldman Sachs Group dropped their price target on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a research report on Wednesday, May 14th. Morgan Stanley lowered their target price on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a research note on Monday, May 12th. Royal Bank of Canada lowered their target price on Chemours from $17.00 to $14.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. Barclays cut their price target on shares of Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday. Finally, UBS Group decreased their price objective on shares of Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th.

Chemours Stock Performance

Shares of NYSE CC traded up $0.11 during mid-day trading on Wednesday, hitting $10.12. The stock had a trading volume of 4,521,080 shares, compared to its average volume of 2,123,951. The company has a debt-to-equity ratio of 6.70, a quick ratio of 0.92 and a current ratio of 1.68. The company has a 50 day moving average of $11.63 and a two-hundred day moving average of $15.74. The firm has a market cap of $1.51 billion, a PE ratio of 17.75 and a beta of 1.76. Chemours has a twelve month low of $9.33 and a twelve month high of $25.98.

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). The business had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.36 billion. Chemours had a net margin of 1.51% and a return on equity of 26.54%. The firm's quarterly revenue was up .4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.32 earnings per share. Research analysts predict that Chemours will post 2.03 EPS for the current fiscal year.

Chemours Dividend Announcement

The business also recently announced a dividend, which will be paid on Monday, June 16th. Investors of record on Monday, May 19th will be given a $0.0875 dividend. The ex-dividend date is Friday, May 16th. This represents a dividend yield of 3.17%. Chemours's dividend payout ratio is presently 175.00%.

Insiders Place Their Bets

In other Chemours news, CFO Shane Hostetter bought 4,450 shares of the company's stock in a transaction that occurred on Monday, May 19th. The stock was purchased at an average price of $11.28 per share, with a total value of $50,196.00. Following the transaction, the chief financial officer now owns 59,694 shares in the company, valued at $673,348.32. This trade represents a 8.06% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.34% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Chemours

A number of hedge funds have recently made changes to their positions in CC. Vanguard Group Inc. boosted its position in Chemours by 8.3% during the 1st quarter. Vanguard Group Inc. now owns 16,487,008 shares of the specialty chemicals company's stock worth $223,069,000 after purchasing an additional 1,263,047 shares during the period. Ameriprise Financial Inc. boosted its position in shares of Chemours by 23.8% in the fourth quarter. Ameriprise Financial Inc. now owns 4,373,172 shares of the specialty chemicals company's stock worth $73,907,000 after buying an additional 839,849 shares during the period. Millennium Management LLC grew its stake in shares of Chemours by 60.4% in the first quarter. Millennium Management LLC now owns 4,022,782 shares of the specialty chemicals company's stock valued at $54,428,000 after buying an additional 1,515,520 shares in the last quarter. American Century Companies Inc. lifted its position in Chemours by 17.5% during the 1st quarter. American Century Companies Inc. now owns 1,909,149 shares of the specialty chemicals company's stock worth $25,831,000 after acquiring an additional 284,130 shares in the last quarter. Finally, Norges Bank purchased a new position in Chemours in the 4th quarter worth approximately $30,702,000. Hedge funds and other institutional investors own 76.26% of the company's stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.